PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Serge Przedborski Selected Research
Parkinson Disease (Parkinson's Disease)
01/2007
Protocol for the MPTP mouse model of Parkinson's disease.
08/2006
Proteasome inhibition and Parkinson's disease modeling.
07/2005
Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice.
05/2005
Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease.
08/2004
MPTP as a mitochondrial neurotoxic model of Parkinson's disease.
07/2004
L-3-hydroxyacyl-CoA dehydrogenase II protects in a model of Parkinson's disease.
02/2004
Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
01/2004
JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.
11/2003
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease.
09/2003
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease.
07/2003
The rotenone model of Parkinson's disease.
06/2003
Nitric oxide and reactive oxygen species in Parkinson's disease.
06/2003
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease.
05/2003
Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease.
05/2003
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
04/2003
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration.
01/2003
Free radical and nitric oxide toxicity in Parkinson's disease.
03/2002
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
Articles by Research Topic
Disease
18
Parkinson Disease (Parkinson's Disease)
01/2007 - 03/2002
2
Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
08/2006 - 05/2002
1
Primary Progressive Aphasia (Progressive Nonfluent Aphasia)
12/2005
1
Parkinsonian Disorders (Parkinsonism)
11/2005
1
Huntington Disease (Huntington's Disease)
12/2003
Drug/Important Bio-Agent (IBA)
7
1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
IBA
01/2007 - 03/2002
2
NADPH Oxidase (NAD(P)H oxidase)
IBA
08/2006 - 05/2003
2
Cyclooxygenase 2 (Cyclooxygenase-2)
IBA
01/2004 - 04/2003
2
Nitric Oxide (Nitrogen Monoxide)
FDA Link
06/2003 - 01/2003
1
Proteasome Endopeptidase Complex (Proteasome)
IBA
08/2006
1
Codon (Codons)
IBA
12/2005
1
Dopamine (Intropin)
FDA Link
Generic
11/2005
1
Peroxidase (Myeloperoxidase)
IBA
07/2005
1
Oxygen
IBA
05/2005
1
Nitrogen
IBA
05/2005
1
Oxidoreductases
IBA
07/2004
1
Caspases
IBA
12/2003
1
Cyclin-Dependent Kinase 5
IBA
11/2003
1
3-Hydroxybutyric Acid (beta-Hydroxybutyric Acid)
IBA
09/2003
1
Rotenone
IBA
07/2003
1
Reactive Oxygen Species (Oxygen Radicals)
IBA
06/2003
1
Cytochromes c (Cytochrome c)
IBA
05/2002
1
Minocycline (Cyclops)
FDA Link
Generic
05/2002